A new report indicates Canada plays a key role in a global coalition to bring forth uniform genomic data sharing.
Bluebee, a company driving genomic data-driven medicine, and Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in long-read sequencing, announced they have integrated the PacBio® de novo assembly pipeline onto the Bluebee® genomics analysis platform. The integration creates a simplified workflow and fully automated, end-to-end data analysis solution that allows
Pharmaceutical companies work towards achieving the goal of bringing new cures or treatments to the market and improve the treatment available for patients.
Q BioMed Inc. (OTCQB: QBIO) and ASDERA LLC today announce a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA’s ASD-002, which is being developed to treat a rare pediatric nonverbal disorder.
By Shelly Kumar
3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF) (the “Company” or “3DS”), is pleased to announce the appointment of Dr. Kevin Little, subject to approval of the TSX Venture Exchange, a leading biomedical scientist and corporate executive, as its new Chief Scientific Officer (“CSO”), effective immediately. In this role, Dr. Little will oversee the
By Pia Rivera
Panda Capital Inc. (TSX-V: PDA.H) (the “Company” or the “Resulting Issuer”) is pleased to provide an update with respect to the proposed amalgamation (the “Transaction”) between ABcann Medicinals Inc. (“ABcann”), the Company and a wholly-owned subsidiary of the Company formed for the purposes of completion of the amalgamation, which will
3D Signatures Inc. (TSXV:DXD) has provided clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloView software platform has the ability to identify patients with Alzheimer’s disease (AD) and, furthermore, distinguish between mild, moderate and severe forms of the disease.
Aevi Genomic Medicine (NASDAQ: GNMX) announced their financial results for 2016 and provide a business update.
Acasti Pharma (NASDAQ:ACST) has appointed two members to its newly announced scientific advisory board.
CannaRoyalty (CSE:CRZ)(CSE:CRZ.CN) (“CannaRoyalty” or the “Company”) is pleased to announce the closing of its previously announced acquisition of a 20% equity stake in Anandia Laboratories Inc. (“Anandia Labs”), a cutting-edge cannabis biotechnology company, in exchange for aggregate consideration of C$4,042,439.09.
Anandia Labs is the only independent Canadian testing facility specializing exclusively
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that the first patient has been dosed in a Phase 1/2 clinical trial to assess the efficacy of its lead investigational drug, AEVI-001 (NFC-1), in children with 22q11.2 Deletion Syndrome (22q DS), a rare disorder caused by an abnormality found
Horizon Discovery Group plc (LSE:HZD) (“Horizon” or the “Company”), the world leader in the application of gene editing technologies, today announces that it has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR
CannaRoyalty (CSE:CRZ) is pleased to announce the signing of a letter of intent (“LOI”) to acquire a 20% equity interest in Anandia Laboratories Inc. Anandia Labs is a cannabis biotechnology company with a focus on providing leading analytical testing services and developing cannabis strains for safe and effective medical applications.